Stocks / Alpha Vantage News Sentiment

Pfizer, Alnylam, BridgeBio gain on Astra/ Ionis setback (PFE:NYSE)

Pfizer, Alnylam Pharma, and BridgeBio Pharma saw their stock prices rise in premarket trading after AstraZeneca and Ionis Pharmaceuticals experienced a late-stage trial setback for a competing drug. These companies all market drugs for ATTR-CM, a rare heart condition. The setback for Astra/Ionis could benefit PFE, ALNY, and BBIO by reducing future competition in the ATTR-CM treatment market.